PRAX-562
Phase 2/3Active 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SCN2A Encephalopathy
Conditions
SCN2A Encephalopathy, SCN8A Encephalopathy
Trial Timeline
Aug 2, 2023 → Mar 1, 2027
NCT ID
NCT05818553About PRAX-562
PRAX-562 is a phase 2/3 stage product being developed by Praxis Precision Medicines for SCN2A Encephalopathy. The current trial status is active. This product is registered under clinical trial identifier NCT05818553. Target conditions include SCN2A Encephalopathy, SCN8A Encephalopathy.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05818553 | Phase 2/3 | Active |
Competing Products
1 competing product in SCN2A Encephalopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PRAX-222 - Initial Dose + PRAX-222 - Initial Ascending Doses + PRAX-222 - Optional Ascending Doses + PRAX-222 - Fixed Doses | Praxis Precision Medicines | Phase 1/2 | 38 |